Exploring MMP14 as a Prognostic and Immune Biomarker in Lung Cancer
-
By
-
Jiajia Xiao
-
Zhenpeng Zhu
-
Fan Zhang
-
Xinsheng Wang
-
January 17, 2026
-
Clinical Scorecard: Exploring MMP14 as a Prognostic and Immune Biomarker in Lung Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Lung Cancer (specifically Non-Small Cell Lung Cancer - NSCLC) |
| Key Mechanisms | MMP14 involvement in ECM remodeling, tumor invasion, and immune modulation. |
| Target Population | Patients with Lung Adenocarcinoma (LUAD) and other NSCLC subtypes. |
| Care Setting | Oncology clinics and research settings. |
Key Highlights
- MMP14 is a prognostic indicator linked to poor outcomes in LUAD.
- High expression of MMP14 correlates with tumor progression and metastasis.
- MMP14 is regulated by NSUN2-mediated RNA methylation modifications.
- MMP14 plays a role in immune cell regulation and inflammatory processes.
- Targeting MMP14 may offer new therapeutic strategies in lung cancer.
Guideline-Based Recommendations
Diagnosis
- Assess MMP14 expression levels as a prognostic biomarker in LUAD.
Management
- Consider targeting MMP14 in therapeutic strategies for advanced LUAD.
Monitoring & Follow-up
- Monitor MMP14 levels to evaluate tumor progression and response to therapy.
Risks
- High MMP14 expression is associated with increased risk of metastasis and poor prognosis.
Patient & Prescribing Data
Patients diagnosed with LUAD and other NSCLC subtypes.
Incorporate MMP14 targeting in treatment plans for patients with high expression levels.
Clinical Best Practices
- Utilize MMP14 as a biomarker for prognosis and treatment response.
- Integrate epigenetic analysis in the evaluation of lung cancer patients.
References
